Concerns mount among Korean drug makers

Published: 2007-10-02 07:00:00

Updated: 2007-10-02 07:00:00

The domestic pharmaceutical sector is expected to face an inevitable blow following the government's recent decision that Daewon Pharm's new oral medication Peluvi (felubiprofen) is not reimbursable.

The Health Insurance Review Agent said on September 20 that it could not accept the insurance price of Peluvi tablets requested by Daewon on account of lacking novelty compared with conventional...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.